Cargando…

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

Since the early 1980s, phosphodiesterase 4 (PDE4) has been an attractive target for the treatment of inflammation-based diseases. Several scientific advancements, by both academia and pharmaceutical companies, have enabled the identification of many synthetic ligands for this target, along with the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crocetti, Letizia, Floresta, Giuseppe, Cilibrizzi, Agostino, Giovannoni, Maria Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370432/ https://www.ncbi.nlm.nih.gov/pubmed/35956914 http://dx.doi.org/10.3390/molecules27154964

Ejemplares similares

PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes
por: Jin, Jian, et al.
Publicado: (2023)

Repurposing strategies on pyridazinone-based series by pharmacophore- and structure-driven screening
por: Floresta, Giuseppe, et al.
Publicado: (2020)

Steered Molecular Dynamics Simulations Study on FABP4 Inhibitors
por: Tomarchio, Rosario, et al.
Publicado: (2023)

Editorial: Serine protease inhibitors and their therapeutic applications
por: Crocetti, Letizia, et al.
Publicado: (2022)

Ligand Growing Experiments Suggested 4-amino and 4-ureido pyridazin-3(2H)-one as Novel Scaffold for FABP4 Inhibition
por: Crocetti, Letizia, et al.
Publicado: (2022)

iVS analysis to evaluate the impact of scaffold diversity in the binding to cellular targets relevant in cancer
por: Cilibrizzi, Agostino, et al.
Publicado: (2018)

FABP4 inhibitors 3D-QSAR model and isosteric replacement of BMS309403 datasets
por: Floresta, Giuseppe, et al.
Publicado: (2018)

Synthesis and analytical characterization of new thiazol-2-(3H)-ones as human neutrophil elastase (HNE) inhibitors
por: Crocetti, Letizia, et al.
Publicado: (2017)

Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N‐formyl peptide receptors agonists
por: Vergelli, Claudia, et al.
Publicado: (2021)

The synthesis and properties of mitochondrial targeted iron chelators
por: Cilibrizzi, Agostino, et al.
Publicado: (2022)

Treating COPD with PDE 4 inhibitors
por: Brown, William M
Publicado: (2007)

4,5-Dihydro-5-Oxo-Pyrazolo[1,5-a]Thieno[2,3-c]Pyrimidine: A Novel Scaffold Containing Thiophene Ring. Chemical Reactivity and In Silico Studies to Predict the Profile to GABA(A) Receptor Subtype
por: Crocetti, Letizia, et al.
Publicado: (2023)

Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes
por: Floresta, Giuseppe, et al.
Publicado: (2022)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System
por: Zhang, Chong, et al.
Publicado: (2017)

Novel Sulfonamide Analogs of Sivelestat as Potent Human Neutrophil Elastase Inhibitors
por: Crocetti, Letizia, et al.
Publicado: (2020)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems
por: Sivakumar, Dakshinamurthy, et al.
Publicado: (2021)

A Yeast-Based Chemical Screen Identifies a PDE Inhibitor That Elevates Steroidogenesis in Mouse Leydig Cells via PDE8 and PDE4 Inhibition
por: Demirbas, Didem, et al.
Publicado: (2013)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

GABA(A) Receptor Modulators with a Pyrazolo[1,5-a]quinazoline Core: Synthesis, Molecular Modelling Studies and Electrophysiological Assays
por: Crocetti, Letizia, et al.
Publicado: (2022)

Identification of pyrazolopyridazinones as PDEδ inhibitors
por: Papke, Björn, et al.
Publicado: (2016)

Correspondence: Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury
por: Cilibrizzi, Agostino
Publicado: (2018)

Novel PDE4 Inhibitors Derived from Chinese Medicine Forsythia
por: Coon, Tiffany A., et al.
Publicado: (2014)

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)
por: Coleman, D. Jackson, et al.
Publicado: (2020)

Synthesis, biological evaluation, and molecular modelling studies of potent human neutrophil elastase (HNE) inhibitors
por: Giovannoni, Maria Paola, et al.
Publicado: (2018)

Isoxazol-5(2H)-one: a new scaffold for potent human neutrophil elastase (HNE) inhibitors
por: Vergelli, Claudia, et al.
Publicado: (2017)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation
por: Vang, Amanda G., et al.
Publicado: (2016)

The efficacy of PDE5 inhibitors in diabetic patients
por: Swiecicka, Agnieszka
Publicado: (2022)

PDE5 inhibitor drugs for use in dementia
por: Hainsworth, Atticus H., et al.
Publicado: (2023)

PDE4D and PDE4B Function in Distinct Subcellular Compartments in Mouse Embryonic Fibroblasts
por: Blackman, Brigitte E., et al.
Publicado: (2011)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
por: Singh, Dave, et al.
Publicado: (2019)

Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice
por: Boyd, Abigail, et al.
Publicado: (2021)

The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils
por: Schioppa, Tiziana, et al.
Publicado: (2022)

PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials
por: Impens, Ann J., et al.
Publicado: (2011)

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development
por: Kayık, Gülru, et al.
Publicado: (2017)

Evaluation of PDE4 inhibition for COPD
por: Wang, Desuo, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_f7oo058ncj5k0gj039qbtjejqu